Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

442
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
442
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

697
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
697
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

855
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
855
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

544
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
544

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Pulmonary Hypertension in Patients With Pulmonary Langerhans Cell Histiocytosis: A Systematic Review and Meta-Analysis.

Cureus·2025
Same author

Delayed Diagnosis of Partial Anomalous Pulmonary Venous Return in an Adult With Pulmonary Hypertension.

Journal of investigative medicine high impact case reports·2025
Same author

Transcatheter Closure of a Rare Right Pulmonary Artery-Left Atrial Fistula in an Adult.

Journal of the Society for Cardiovascular Angiography & Interventions·2024
Same author

The impact of supraventricular arrhythmias on the outcomes of guideline-compliant implantable cardioverter defibrillator programming.

Journal of cardiovascular electrophysiology·2024
Same author

Unraveling a rare presentation of bivalvular infective endocarditis using POCUS.

Clinical case reports·2023
Same author

Meteorological Influence on Atrial Fibrillation and Flutter: A Nationwide Observational Study in South Korea (2010-2022).

Cureus·2023
Same journal

Sweating the Details: A Reflective Pause in our Procedural Workflow.

Cardiac electrophysiology clinics·2026
Same journal

Patent Foramen Ovale and Atrial Septal Defect.

Cardiac electrophysiology clinics·2026
Same journal

Patent Foramen Ovale Embryology, Anatomy, and Physiology.

Cardiac electrophysiology clinics·2026
Same journal

Management of Arrhythmias in the Cardiovascular Intensive Care Unit.

Cardiac electrophysiology clinics·2026
Same journal

Left Ventricular Assist Device Emergencies: Diagnosis and Management.

Cardiac electrophysiology clinics·2026
Same journal

Advanced Critical Care Techniques in the Field.

Cardiac electrophysiology clinics·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K

Inappropriate Implantable Cardioverter-Defibrillator Therapy.

Sivakumar Ardhanari1, Ashok J Shah, Nitesh Gadeela

  • 1Arrhythmia Services, Thoracic and Cardiovascular Institute, Sparrow Health System, Michigan State University, Lansing, MI 48910, USA.

Cardiac Electrophysiology Clinics
|August 4, 2017
PubMed
Summary
This summary is machine-generated.

Preventing inappropriate implantable cardioverter-defibrillator (ICD) therapies remains a challenge, primarily due to atrial arrhythmias. Personalized programming is key to managing these events and improving patient quality of life.

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.4K

Related Experiment Videos

Last Updated: Feb 25, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.4K

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Implantable cardioverter-defibrillators (ICDs) have advanced, but inappropriate therapy delivery remains a significant issue for recipients.
  • Atrial arrhythmias are identified as the primary cause of inappropriate ICD therapies, yet effective prevention strategies are lacking.

Purpose of the Study:

  • To review the challenges in preventing inappropriate implantable cardioverter-defibrillator (ICD) therapies.
  • To discuss the role of atrial arrhythmias and tachycardia detection discriminators in inappropriate therapies.
  • To highlight the importance of personalized programming for ICD recipients.

Main Methods:

  • Literature review of current implantable cardioverter-defibrillator (ICD) therapy guidelines and research.
  • Analysis of the causes and consequences of inappropriate ICD therapies.
  • Discussion of available programming options and patient-specific considerations.

Main Results:

  • Atrial arrhythmias are the leading cause of inappropriate ICD therapies, posing a challenge for physicians.
  • Current tachycardia detection discriminators are helpful but no single combination is ideal for all patients.
  • Personalized programming based on individual patient characteristics is the most viable approach to ameliorate, though not eliminate, inappropriate therapies.

Conclusions:

  • Effective prevention of inappropriate implantable cardioverter-defibrillator (ICD) therapies requires a deep understanding of patient-specific factors.
  • While a universal algorithm may not be feasible, optimizing ICD programming can significantly improve patient outcomes and quality of life.